Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Saves CAD2bn Through Pricing Deal

But CGPA Warns Over Increasing Reliance On India And China For Supply

Executive Summary

A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.

You may also be interested in...



Canada’s CGPA Welcomes Move Towards National Pharmacare

A renewed commitment from Canada’s government to a universal national pharmacare program, included in the latest federal budget, has been welcomed by the country’s generics and biosimilars industry.

Canadian Body Calls For Investment In Domestic Production

In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.

Canadian Body Addresses Shortages Risk

The CGPA and Biosimilars Canada have acknowledged the risk of local shortages amid the coronavirus crisis, after Health Canada advised Canadians that buying more medicine than usual could lead to local supply disruptions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel